Literature DB >> 1745023

Decreased postheparin lipolytic activity in renal transplant recipients with cyclosporin A.

K Derfler1, M Hayde, G Heinz, M M Hirschl, G Steger, A C Hauser, P Balcke, K Widhalm.   

Abstract

The patterns of hyperlipidemia in renal transplant recipients (RTRs) are more variable than in the uremic state, showing increases in both very low-density lipoprotein (VLDL) and low density lipoprotein (LDL). This has been attributed, at least in part, to immunosuppressive therapy, especially to treatment with corticosteroids. Postheparin lipolytic activity (PHLA) was determined in 28 RTRs. Sixteen patients presenting with hyperlipidemia comprised group A, who were aged 49.8 +/- 13.5 years, and had a cholesterol of 8.24 +/- 1.86 mmol/liter, triglycerides of 6.02 +/- 3.33 mmol/liter. Twelve patients presenting cholesterol and triglyceride values within the normal range were in group B, and were aged 48.6 +/- 13.3 years. All RTRs received cyclosporin A (CsA) twice daily orally, which were divided in two equal doses and adjusted to provide CsA blood trough levels (RIA) in a range of 250 to 350 ng/ml. Twenty-one RTRs were additionally treated by alternate-day corticosteroids, whereas seven patients had CsA on their sole immunosuppressive agent. PHLA (mumol free fatty acids/ml/hr, given 10 and 20 min after 100 U/heparin kg body wt intravenously) was commonly reduced in RTRs (group A at 10/20 min: 5.6 +/- 1.1/5.26 +/- 1.2; group B: 8.26 +/- 2.91/8.38 +/- 3.44) as compared to the values obtained in healthy controls (15.3 +/- 2.9/17.2 +/- 5.0). This was mainly due to a reduction of the activity of the hepatic triglyceride lipase, and to a minor extent to a reduced activity of peripheral lipoprotein lipase. There was no statistically significant difference of PHLA in RTRs with or without corticosteroid treatment.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1745023     DOI: 10.1038/ki.1991.266

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  11 in total

1.  The circFASN/miR-33a pathway participates in tacrolimus-induced dysregulation of hepatic triglyceride homeostasis.

Authors:  Chenzhi Zhang; Kangchen Chen; Rongli Wei; Guanghan Fan; Xuechun Cai; Li Xu; Beini Cen; Jianguo Wang; Haiyang Xie; Shusen Zheng; Xiao Xu
Journal:  Signal Transduct Target Ther       Date:  2020-03-27

Review 2.  The metabolic effects of cyclosporin and tacrolimus.

Authors:  P Marchetti; R Navalesi
Journal:  J Endocrinol Invest       Date:  2000 Jul-Aug       Impact factor: 4.256

Review 3.  Metabolic mechanisms for and treatment of NAFLD or NASH occurring after liver transplantation.

Authors:  Amedeo Lonardo; Alessandro Mantovani; Salvatore Petta; Amedeo Carraro; Christopher D Byrne; Giovanni Targher
Journal:  Nat Rev Endocrinol       Date:  2022-07-15       Impact factor: 47.564

Review 4.  Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors Use for Atherogenic Dyslipidemia in Solid Organ Transplant Patients.

Authors:  Gianluigi Cuomo; Giuseppe Cioffi; Anna Di Lorenzo; Francesca Paola Iannone; Giuseppe Cudemo; Anna Maria Iannicelli; Mario Pacileo; Antonello D'Andrea; Carlo Vigorito; Gabriella Iannuzzo; Francesco Giallauria
Journal:  J Clin Med       Date:  2022-06-06       Impact factor: 4.964

Review 5.  Metabolic consequences of modern immunosuppressive agents in solid organ transplantation.

Authors:  Oluwatoyin Bamgbola
Journal:  Ther Adv Endocrinol Metab       Date:  2016-03-30       Impact factor: 3.565

Review 6.  Dyslipidemia in Dermatological Disorders.

Authors:  Chetana Shenoy; Manjunath Mala Shenoy; Gururaja K Rao
Journal:  N Am J Med Sci       Date:  2015-10

7.  Host-Parasite Interaction in Sarcoptes scabiei Infestation in Porcine Model with a Preliminary Note on Its Genetic Lineage from India.

Authors:  Arun Kumar De; Sneha Sawhney; Samiran Mondal; Perumal Ponraj; Sanjay Kumar Ravi; Gopal Sarkar; Santanu Banik; Dhruba Malakar; Kangayan Muniswamy; Ashish Kumar; Arvind Kumar Tripathi; Asit Kumar Bera; Debasis Bhattacharya
Journal:  Animals (Basel)       Date:  2020-12-07       Impact factor: 2.752

Review 8.  Dyslipidemia in Transplant Patients: Which Therapy?

Authors:  Gabriella Iannuzzo; Gianluigi Cuomo; Anna Di Lorenzo; Maria Tripaldella; Vania Mallardo; Paola Iaccarino Idelson; Caterina Sagnelli; Antonello Sica; Massimiliano Creta; Javier Baltar; Felice Crocetto; Alessandro Bresciani; Marco Gentile; Armando Calogero; Francesco Giallauria
Journal:  J Clin Med       Date:  2022-07-14       Impact factor: 4.964

Review 9.  Haematological Drugs Affecting Lipid Metabolism and Vascular Health.

Authors:  Antonio Parrella; Arcangelo Iannuzzi; Mario Annunziata; Giuseppe Covetti; Raimondo Cavallaro; Emilio Aliberti; Elena Tortori; Gabriella Iannuzzo
Journal:  Biomedicines       Date:  2022-08-10

10.  The circFASN/miR-33a pathway participates in tacrolimus-induced dysregulation of hepatic triglyceride homeostasis.

Authors:  Chenzhi Zhang; Kangchen Chen; Rongli Wei; Guanghan Fan; Xuechun Cai; Li Xu; Beini Cen; Jianguo Wang; Haiyang Xie; Shusen Zheng; Xiao Xu
Journal:  Signal Transduct Target Ther       Date:  2020-03-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.